Vpriv 2019 U.S. PROMOTIONAL AUDIT REPORT

Vpriv 2019 U.S. PROMOTIONAL AUDIT REPORT

  • July 2020 •
  • 28 pages •
  • Report ID: 5210739 •
  • Format: PDF
The 5 Key Questions Addressed by this Report:
• How many physicians were reached by Vpriv through reportable promotional activity in 2019 and how does this compare to its peer set in the Gaucher’s Disease market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Shire’s depth of coverage vary within key specialties (e.g., Pediatric Medicine, Hematology/Oncology, Internal Medicine, Family Medicine, Gastroenterology, and Medical Genetics) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Vpriv throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Vpriv in 2019?

Data Sources and Methodology:
• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 700 paid interactions across 600 physicians made on behalf of Vpriv were carefully examined to support our analysis. In addition, interaction data from 3 peer products (e.g. Cerdelga, Cerezyme, and Elelyso ) was leveraged to provide benchmarking and market insights.